Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINIVELLE vs MENEST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estradiol binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and regulation of target tissues including reproductive, cardiovascular, skeletal, and CNS systems.
Menest is a conjugated estrogens formulation that binds to estrogen receptors (ERα and ERβ), activating genomic signaling pathways that regulate gene transcription. This leads to effects such as proliferation of endometrial and breast tissue, modulation of gonadotropin release, and maintenance of bone density.
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (use for >5 years only if clearly needed)
Moderate to severe vasomotor symptoms associated with menopause,Vulvar and vaginal atrophy,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (in women at significant risk),Palliative treatment of advanced androgen-dependent carcinoma of the prostate,Palliative treatment of advanced breast cancer in selected postmenopausal women
Transdermal: Apply 0.025-0.1 mg/day patch twice weekly (every 3-4 days).
0.625 mg orally once daily for estrogen replacement; dosage range 0.3-1.25 mg daily based on clinical response.
Terminal half-life: 12-18 hours for estradiol; clinical context: once-daily or twice-weekly dosing maintains steady-state concentrations.
The terminal elimination half-life of conjugated estrogens is approximately 10-24 hours. The half-life of estrone, the primary metabolite, is about 12-18 hours. This supports once-daily dosing.
Primarily hepatic metabolism via CYP3A4 to estrone and estriol, followed by conjugation (glucuronidation, sulfation).
Conjugated estrogens are metabolized primarily in the liver via hydroxylation and conjugation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2D6) and undergo enterohepatic recirculation.
Renal: 80-90% as glucuronide and sulfate conjugates; Fecal: 10-20% via bile; <1% unchanged.
Estrogens are excreted primarily in urine (about 90-95%) as glucuronide and sulfate conjugates. The remaining 5-10% is excreted in feces via bile. Less than 5% is excreted unchanged.
98% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Estrogens are approximately 50-80% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. Estrone is about 16% bound to SHBG and 80% to albumin; estradiol has higher SHBG affinity.
Approximately 1.2-1.5 L/kg; extensive distribution into tissues.
The apparent volume of distribution for conjugated estrogens is not well-defined due to tissue binding. For estradiol, Vd is approximately 1.2 L/kg, indicating extensive distribution into tissues and fat.
Transdermal: approximately 82% of dose absorbed (avoid first-pass metabolism); oral: <5% due to extensive hepatic first-pass.
Oral bioavailability of conjugated estrogens is approximately 40-50% due to first-pass hepatic metabolism. The tablet formulation is designed to deliver a consistent dose; enteric-coated tablets may have slightly different bioavailability.
No specific dosage adjustment recommended; use with caution in severe impairment.
No specific dosing adjustment recommended; use with caution in severe renal impairment.
Contraindicated in severe hepatic disease (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use lowest effective dose.
Contraindicated in severe hepatic disease (Child-Pugh class C); for mild to moderate impairment (Child-Pugh A or B), use lowest effective dose and monitor liver function.
Safety and efficacy not established; not FDA-approved for pediatric use.
Not approved for use in pediatric patients.
Use lowest effective dose; monitor for thromboembolic events and malignancy; consider shorter duration.
Initiate at lowest effective dose (0.3 mg daily) due to increased sensitivity and risk of adverse effects; monitor closely for thromboembolic events and malignancy.
Estrogens increase the risk of endometrial cancer in women with an intact uterus. Use progestin when uterus is present. Do not use for prevention of cardiovascular disease or dementia. Increased risk of probable dementia in women ≥65 years. Increased risk of breast cancer, stroke, DVT, and pulmonary embolism.
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Unopposed estrogen use increases the risk of endometrial hyperplasia and carcinoma. Estrogens should not be used in women with undiagnosed abnormal genital bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Estrogens increase the risk of venous thromboembolism, stroke, and myocardial infarction.
Cardiovascular disorders (stroke, MI, DVT), malignant neoplasms (endometrial, breast, ovarian), dementia, gallbladder disease, hypercalcemia, visual abnormalities, hereditary angioedema, exacerbation of endometriosis, and fluid retention. Minimize dose and duration.
Cardiovascular disorders: increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction,Malignant neoplasms: increased risk of endometrial cancer and possibly breast cancer,Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hypocalcemia,Hereditary angioedema,Exacerbation of endometriosis,Visual abnormalities,Dementia risk (when initiated in women >65 years),Jaundice and liver function abnormalities
Undiagnosed abnormal genital bleeding, known/suspected breast cancer (except certain metastatic cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history thereof, active arterial thromboembolic disease (e.g., stroke, MI), known protein C/protein S/antithrombin deficiency, liver impairment or disease, known pregnancy, hypersensitivity to estradiol or components.
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Active liver disease or impaired liver function,Known or suspected breast cancer (except in selected metastatic cases),Known or suspected estrogen-dependent neoplasia (e.g., endometrial cancer),Active or history of venous thromboembolism,Active or history of arterial thromboembolism (e.g., stroke, MI),Hypersensitivity to estrogens or any ingredient in Menest
Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism and increase estradiol levels. St. John's wort may induce estrogen metabolism and reduce efficacy. No significant interactions with other foods.
Grapefruit and grapefruit juice may increase serum estrogen levels via CYP3A4 inhibition and should be avoided. High-fat meals may increase absorption; take consistently with or without food. Vitamin C supplements may increase estrogen levels.
Estrogens, including estradiol (MINIVELLE), are contraindicated in pregnancy. First trimester exposure is associated with a risk of congenital anomalies, particularly cardiovascular and urogenital defects. Second and third trimester exposure may increase risk of fetal reproductive tract abnormalities, including vaginal adenosis and clear cell adenocarcinoma in female offspring. Estrogens should not be used during pregnancy.
First trimester: Increased risk of congenital anomalies, including cardiovascular and urogenital defects, with non-contraceptive estrogen use. Second and third trimesters: Associated with fetal genital tract abnormalities, increased risk of spontaneous abortion, and preterm delivery. Estrogens are contraindicated in pregnancy.
Estradiol is excreted in human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. Infant exposure is considered low, but estrogens may reduce milk production and composition. Use during breastfeeding is generally not recommended, especially in the early postpartum period. Consider alternatives.
Estrogens are excreted in human milk in small amounts. M/P ratio not established. Use during breastfeeding is not recommended as it may reduce milk production and affect infant development.
Estrogen metabolism is altered in pregnancy due to increased hepatic clearance and plasma volume. However, MINIVELLE is contraindicated in pregnancy; therefore, no dose adjustment recommendations are provided. Use is not advised under any circumstances.
No dose adjustments recommended; drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy include increased clearance, but no safe dose established.
Minivelle (estradiol transdermal system) delivers continuous estradiol for hormone therapy. Apply to clean, dry, intact skin on lower abdomen or upper buttock; avoid breasts and waistline. Rotate application sites with at least 1-week interval. Do not apply to oily, irritated, or sunburned skin. If patch falls off, reapply or replace with a new patch; maintain same schedule. Monitor for signs of thromboembolism, stroke, or breast cancer. Discontinue if migraine develops. Use lowest effective dose for shortest duration.
Menest (esterified estrogens) contains a mixture of estrogenic substances, primarily sodium estrone sulfate, with lower potency than conjugated equine estrogens (CEE) due to absence of equilin. For vasomotor symptoms, start at lowest effective dose; consider estradiol-based alternatives for better pharmacokinetic profile. Monitor for thromboembolic events; avoid in patients with active liver disease or unexplained vaginal bleeding. Absorption may be impaired in patients with GI malabsorption disorders.
Apply patch once weekly on the same day.,Choose a clean, dry area on your lower belly or upper buttock; never place on breasts.,Rotate application sites; do not use the same spot twice within 1 week.,If patch falls off, reapply a new one; if it has been off for more than 8 hours, apply a new patch and note the day.,Do not expose patch to direct heat sources (heating pads, saunas, sunbathing) as it may increase drug absorption.,Report any sudden severe headache, vision changes, chest pain, shortness of breath, or leg swelling/pain.,Avoid grapefruit juice and St. John's wort, as they may alter drug effectiveness.,Do not smoke while using this medication; smoking increases risk of blood clots and heart disease.
Take with food or milk to reduce gastrointestinal upset.,Report any sudden severe headache, vision changes, chest pain, or leg swelling immediately.,Avoid grapefruit juice and grapefruit products as they may increase estrogen levels.,Do not smoke while using this medication; smoking increases risk of blood clots and stroke.,Inform your physician of any history of breast cancer, uterine cancer, or blood clotting disorders.,Use the lowest effective dose for the shortest duration possible.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINIVELLE vs MENEST, answered by our medical review team.
MINIVELLE is a Estrogen Replacement that works by Estradiol binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and regulation of target tissues including reproductive, cardiovascular, skeletal, and CNS systems.. MENEST is a Estrogen Replacement Therapy that works by Menest is a conjugated estrogens formulation that binds to estrogen receptors (ERα and ERβ), activating genomic signaling pathways that regulate gene transcription. This leads to effects such as proliferation of endometrial and breast tissue, modulation of gonadotropin release, and maintenance of bone density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINIVELLE and MENEST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINIVELLE is: Transdermal: Apply 0.025-0.1 mg/day patch twice weekly (every 3-4 days).. The standard adult dose of MENEST is: 0.625 mg orally once daily for estrogen replacement; dosage range 0.3-1.25 mg daily based on clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINIVELLE and MENEST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINIVELLE is classified as Category C. Estrogens, including estradiol (MINIVELLE), are contraindicated in pregnancy. First trimester exposure is associated with a risk of congenital anomalies, particularly cardiovascula. MENEST is classified as Category C. First trimester: Increased risk of congenital anomalies, including cardiovascular and urogenital defects, with non-contraceptive estrogen use. Second and third trimesters: Associat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.